OPRK1 — Kappa Opioid Receptor

📖 Wiki Page

gene1627 wordssynced 2026-04-02

OPRK1 — Kappa Opioid Receptor

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">OPRK1 — Kappa Opioid Receptor</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>OPRK1</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Kappa-opioid receptor (KOR)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8q11.23</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4985</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P41145</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>426 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~48 kDa</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Class A GPCR (rhodopsin family)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>KOR, OPRK</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>CNS (striatum, cortex, hippocampus, hypothalamus, spinal cord), peripheral sensory neurons, immune cells</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

...

OPRK1 — Kappa Opioid Receptor

Overview

OPRK1 encodes the kappa-opioid receptor (KOR), a seven-transmembrane G protein-coupled receptor (GPCR) that binds endogenous dynorphins and a variety of synthetic and natural ligands. KOR is widely expressed throughout the central and peripheral nervous systems, where it modulates pain perception, mood, reward processing, stress responses, and neuroinflammation[@kreek2013].

Unlike mu-opioid receptors (encoded by [OPRM1](/genes/oprm1)) that mediate euphoria and analgesia, KOR activation is associated with dysphoric and anxiogenic effects. This unique pharmacology has made KOR a compelling target for treating substance use disorders, chronic pain, and mood disorders. More recently, KOR signaling has been implicated in [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and other neurodegenerative conditions through its effects on dopamine signaling, neuroinflammation, and cellular stress responses[@fallon2017].

Gene and Protein Information

Normal Function

Ligand Binding and Selectivity

KOR binds the endogenous opioid peptides dynorphin A (1-17), dynorphin A (1-8), and dynorphin B with high affinity and selectivity over mu and delta opioid receptors. Dynorphins are the only known endogenous ligands with significant KOR selectivity; beta-endorphin and enkephalins bind primarily to mu and delta receptors[@bruchas2011].

Exogenous KOR-selective ligands include:

Agonists: Salvinorin A (the active component of Salvia divinorum), U-50488, U-69593, spiradoline, enadoline
Antagonists: Nor-binaltorphimine (nor-BNI), JDTic, CVL-231, bupropione
Partial agonists: Triazole 1.1 (ALP-0101)

Signal Transduction

KOR couples primarily to Gαi/Gαo proteins, leading to:

Adenylyl cyclase inhibition: Decreased cAMP production, reduced PKA activity

MAPK pathway activation: ERK1/2, p38, and JNK pathways are activated in a cell-type-dependent manner

PI3K/Akt signaling: KOR activation can promote neuronal survival through Akt phosphorylation

Ion channel modulation: Opening of inwardly rectifying potassium channels (GIRKs), inhibition of voltage-gated calcium channels

Beta-arrestin recruitment: Phosphorylation of KOR by GRKs leads to beta-arrestin 2 binding, receptor internalization, and activation of MAPK pathways[@land2018]

Mermaid diagram (expand to render)

Anatomical Distribution and Functions

Striatum and basal ganglia: KOR is highly expressed in the [striatum](/brain-regions/striatum), particularly in medium spiny neurons and dopaminergic nerve terminals. KOR activation modulates dopamine release and behavior. It inhibits dopamine release from the [substantia nigra pars compacta](/brain-regions/substantia-nigra) and [ventral tegmental area](/brain-regions/ventral-tegmental-area), contributing to its dysphoric effects and role in addiction[@prus2019].

Hypothalamus and HPA axis: KOR activation in the hypothalamus promotes stress responses and dynorphin release feeds back to activate KOR, creating a self-reinforcing stress loop. KOR antagonists can block stress-induced behaviors and drug seeking[@bruchas2011].

Hippocampus: KOR is expressed in the [hippocampus](/brain-regions/hippocampus), particularly in CA1 and dentate gyrus. KOR activation inhibits glutamate release and impairs synaptic plasticity. Dynorphin levels increase with neuronal activity, providing negative feedback on excitability.

Spinal cord and pain pathways: KOR is expressed in the dorsal horn of the spinal cord, where it inhibits pain transmission by reducing glutamate and substance P release from primary afferent [neurons](/entities/neurons)[@metcalf2010].

Peripheral sensory neurons: KOR in sensory ganglia modulates nociception and neuropathic pain. KOR agonists reduce pain by acting on peripheral nerve terminals.

Endogenous Dynorphin-KOR System

The dynorphin-KOR system is distinct from other opioid systems:

Dynorphin A (1-17) is the primary endogenous agonist; it is processed from pre-prodynorphin (encoded by [PDYN](/genes/pdyn))
Dynorphin release is activity-dependent and often co-released with glutamate or as a stress response
KOR activation produces analgesia at spinal level but dysphoria and dissociation at brain level
Persistent KOR activation contributes to anxiety, depression, and stress-related disorders[@land2018]

Role in Neurodegeneration

Parkinson's Disease

Dopaminergic modulation: The dynorphin-KOR system is closely integrated with dopaminergic circuits. In PD, dopaminergic neuron degeneration leads to compensatory changes in dynorphin expression. Studies show elevated dynorphin levels in the [striatum](/brain-regions/striatum) and [substantia nigra](/brain-regions/substantia-nigra) in PD models and patients[@wang2019].

KOR-dopamine interactions: KOR activation inhibits dopamine release from terminals in the striatum through presynaptic mechanisms. This creates a feedforward loop: as dopamine neurons degenerate, dynorphin-KOR signaling is dysregulated, further reducing dopamine tone and exacerbating motor symptoms[@chus2019].

Alpha-synuclein interactions: Emerging evidence links KOR signaling to alpha-synuclein ([SNCA](/genes/snca)) pathology. KOR activation may influence the aggregation or clearance of alpha-synuclein, and conversely, alpha-synuclein pathology may alter KOR function[@fan2019].

Therapeutic potential: KOR antagonists are being explored to:

Reduce the inhibitory effect on remaining dopaminergic neurons
Restore dopaminergic tone
Treat dyskinesias induced by L-DOPA therapy
Address depression and anxiety comorbidity in PD[@whittaker2022]

Alzheimer's Disease

Neuroinflammation modulation: The dynorphin-KOR system modulates neuroinflammation through effects on microglia and astrocytes. KOR activation on glial cells can either promote or suppress inflammatory responses depending on cell type and context[@campos2021].

Dynorphin elevation in AD: Elevated dynorphin levels have been reported in AD brains, potentially as a compensatory response to synaptic dysfunction and neuronal stress. High dynorphin may contribute to cognitive impairment through KOR-mediated inhibition of synaptic plasticity in the hippocampus[@wagner2020].

Cognitive effects: KOR activation impairs hippocampal synaptic plasticity, including long-term potentiation (LTP). This is mediated by inhibition of glutamate release and modulation of NMDA receptor function. KOR antagonists have been shown to enhance memory in animal models.

Therapeutic targeting: KOR antagonists could potentially:

Enhance hippocampal plasticity and improve memory
Reduce neuroinflammation
Address the depression and apathy common in AD[@fallon2017]

Chronic Pain and Neuropathic States

Neuropathic pain: KOR is implicated in chronic pain states, including chemotherapy-induced peripheral neuropathy and diabetic neuropathy. KOR agonists have antinociceptive effects at the spinal level, but brain-level KOR activation can produce aversion[@metcalf2010].

Stress-induced pain amplification: Chronic stress, which is a risk factor for neurodegeneration, dysregulates the dynorphin-KOR system, amplifying pain sensitivity and contributing to a vicious cycle of stress-pain-inflammation.

Drug Addiction and Compulsive Behaviors

Dynorphin and addiction: The dynorphin-KOR system mediates the dysphoric component of addiction withdrawal. KOR activation promotes reinstatement of drug seeking and contributes to the negative emotional state that drives addiction relapse[@shippenberg2007].

PARK2 links: Given that dynorphin is processed from [PDYN](/genes/pdyn), and PDYN is a transcriptional target of REST (repressor element-1 silencing transcription factor), mutations in PDYN itself could contribute to dynorphin system dysfunction in neurodegeneration.

Molecular Mechanisms

Receptor Signaling Bias

KOR exhibits ligand bias (functional selectivity), where different ligands preferentially activate different downstream pathways:

G protein signaling (cAMP inhibition): Linked to analgesia
Beta-arrestin recruitment (GRK phosphorylation): Linked to dysphoric effects
ERK activation: Context-dependent

This has guided the development of peripherally-restricted KOR agonists (for analgesia without dysphoria) and biased KOR antagonists that block beta-arrestin signaling while preserving potential beneficial effects.

Receptor Trafficking and Regulation

KOR undergoes:

Phosphorylation by G protein-coupled receptor kinases (GRKs)
Beta-arrestin 2 binding and internalization
Recycling to the membrane or degradation in lysosomes

Sustained agonist exposure leads to receptor desensitization and downregulation. This trafficking is modulated by phosphorylation at specific serine and threonine residues in the C-terminal tail.

Interaction with Other Opioid Receptors

KOR can form heterodimers with mu ([OPRM1](/genes/oprm1)) and delta ([OPRD1](/genes/oprd1)) opioid receptors, creating complexes with unique pharmacological properties. Heterodimerization can alter ligand binding, signal transduction, and trafficking of both partners.

Therapeutic Development

KOR Antagonists in Clinical Trials

Several KOR antagonists are in development:

Aticaprant (CRL-831) — in Phase II trials for major depressive disorder and opioid use disorder
Buprenorphine (partial KOR agonist) — approved for opioid use disorder
PF-4456322 — selective KOR antagonist for addiction
LY-D9T — in preclinical development for neurological disorders

KOR Agonists (Peripherally Restricted)

Peripherally-restricted KOR agonists like asimadoline have been tested for chronic pain without CNS dysphoric effects.

Challenges

On-target toxicity: KOR antagonism can cause motor impairment at high doses
Species differences: Rodent and human KOR pharmacology differ significantly
Phasic vs. tonic dynorphin: Chronic vs. acute KOR activation produces different outcomes
HPA axis effects: KOR ligands can affect the stress response system[@chern2022]

Gene Interactions and Network

PDYN — encodes pre-prodynorphin, precursor of endogenous KOR ligands
OPRM1 — mu-opioid receptor; heterodimerization with KOR
OPRD1 — delta-opioid receptor; heterodimerization with KOR
GRK3 — phosphorylates KOR, regulates desensitization
ARRB2 — beta-arrestin 2; recruits signaling complexes
CREB1 — transcriptional target of KOR signaling
MAPK1/3 — ERK1/2; activated by KOR via beta-arrestin
AKT1 — neuroprotective signaling downstream of KOR[@reiner2018]

Genetics and Variants

OPRK1 polymorphisms associated with:

rs6478549 — linked to addiction vulnerability (alcohol dependence)
rs7815826 — associated with pain sensitivity
rs9643456 — implicated in major depression
rs35618852 — functional variant affecting receptor expression

These variants may influence an individual's susceptibility to stress-related disorders, chronic pain, and possibly neurodegenerative disease[@bortolato2007].

Research Challenges and Open Questions

KOR subtypes and signaling diversity: Are there functionally distinct KOR populations (e.g., neuronal vs. glial) that could be selectively targeted?

Dynorphin-KOR in PD progression: Is dysregulated dynorphin a cause or consequence of dopaminergic degeneration? Can KOR modulation slow disease progression?

KOR and neuroinflammation: How does KOR signaling on microglia and astrocytes influence the neuroinflammatory response in AD and PD?

Peripherally-restricted strategies: Can peripheral KOR modulation provide therapeutic benefit without CNS dysphoria?

Biased agonism: Can selectively activating G-protein signaling (without beta-arrestin recruitment) provide analgesia without dysphoria?

Combination therapies: Could KOR modulators synergize with dopaminergic drugs in PD or cholinesterase inhibitors in AD?

OPRK1 — Kappa Opioid Receptor

OPRK1 — Kappa Opioid Receptor

Overview

OPRK1 — Kappa Opioid Receptor

Overview

Gene and Protein Information

Normal Function

Ligand Binding and Selectivity

Signal Transduction

Anatomical Distribution and Functions

Endogenous Dynorphin-KOR System

Role in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Chronic Pain and Neuropathic States

Drug Addiction and Compulsive Behaviors

Molecular Mechanisms

Receptor Signaling Bias

Receptor Trafficking and Regulation

Interaction with Other Opioid Receptors

Therapeutic Development

KOR Antagonists in Clinical Trials

KOR Agonists (Peripherally Restricted)

Challenges

Gene Interactions and Network

Genetics and Variants

Research Challenges and Open Questions

See Also